GLP-1 medications show cardiopulmonary benefits for obstructive sleep apnea

Research scheduled for presentation at the CHEST 2026 conference indicates that glucagon-like peptide 1, or GLP-1, medications provide broad positive cardiopulmonary effects. Managed Healthcare Executive reported that the findings link these drugs to a reduced risk of acute respiratory failure. Bioengineer.org separately reported that the CHEST 2026 meeting presents new research spanning asthma, critical care, and other respiratory conditions. [1][2]

Obesity is a major contributing factor in the development of obstructive sleep apnea. Christopher N. Schmickl of the Division of Pulmonary, Critical Care and Sleep Medicine is examining how GLP-1 drugs can treat the condition, according to Managed Healthcare Executive. Questions remain regarding the full extent of these treatments for sleep-related breathing disorders. [1]

Obstructive sleep apnea is the most common sleep-related breathing disorder and causes recurrent episodes of partial or complete upper airway obstruction during sleep. These breathing pauses lead to disruptions in sleep and drops in blood oxygen saturation. Tirzepatide is a GLP-1 receptor agonist and gastric inhibitory polypeptide analog administered through weekly subcutaneous injections. As FTMQ Health reported earlier, other treatments like pitolisant also target sleep apnea symptoms. [1][3][4][5]

In late 2024, the United States Food and Drug Administration approved tirzepatide under the brand name Zepbound to treat severe obstructive sleep apnea and aid weight loss, Managed Healthcare Executive and Wikipedia noted. Tirzepatide is also sold under the brand name Mounjaro to treat type 2 diabetes. Researchers continue to evaluate how these metabolic therapies lower cardiovascular and respiratory risks in patients. [1][3]